The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine reserves.

The freeze-dried formulation provides flexibility with regard to storage and shelf life. The Food and Drug Administration (FDA) has approved a new freeze-dried formulation of Jynneos ® (smallpox ...

The US Food and Drug Administration (FDA) has approved the freeze-dried formulation of Bavarian Nordic’s smallpox and mpox vaccine in a move expected to provide flexibility in stockpiling the jab.

Approved by the FDA in 2019, JYNNEOS was the first smallpox vaccine successfully developed under Project BioShield, a program created by the U.S. Congress in 2004 to accelerate the research ...

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ...

Approved by the FDA in 2019, JYNNEOS was the first smallpox vaccine successfully developed under Project BioShield, a program created by the U.S. Congress in 2004 to accelerate the research ...